- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcole…Endpoints · 2mo ago↗ source
- <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]><![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>onclive · 2mo ago↗ source
- Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AIA startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork C…